Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: Does β-Lactam Class Matter?

Abstract

We analyzed the impact of vancomycin (VAN) combined with adjuvant β-lactam therapy (Combo) on persistent (≥5 days) methicillin-resistant <i>Staphylococcus aureus</i> bacteremia versus VAN alone by using pooled data from two previously published observational studies (<i>n</i> = 156). Combo was inversely associated with persistent bacteremia (adjusted odds ratio, 0.460; 95% confidence interval, 0.229 to 0.923). Acute kidney injury was more common with Combo than with VAN (18.9% and 7.6%, respectively; <i>P</i> = 0.062).